Streetbeat News

Stock Prices

NRIX

Nurix Therapeutics has presented new clinical evidence at the AACR 2024 Annual Meeting, showing CNS activity of NX-5948, an orally available BTK degrader in development for B cell malignancies. The data includes case studies of patients with CLL and PCNSL, highlighting the potential for broader application in autoimmune disorders with CNS involvement.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 5:16 pm

CVX

Recent options trading activity for Chevron (NYSE:CVX) shows a bullish sentiment among investors, with 63% of trades being bullish and 37% bearish. Significant trading activity has been observed, with a total of 11 trades, including 4 puts and 7 calls, indicating an expected price range for Chevron's stock between $125.0 and $230.0 over the next three months. Chevron, a major integrated energy company, has a current stock price of $161.67, showing a slight increase of 0.25%. The company is expected to announce its earnings in 17 days, and its trading volume and RSI indicators suggest the stock may be overbought.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 5:16 pm

VKTX

Deep-pocketed investors have shown a bearish sentiment towards Viking Therapeutics (NASDAQ:VKTX), as revealed by Benzinga's tracking of public options records. The analysis of 13 extraordinary options activities indicates a divided mood among investors, with a significant lean towards bearishness. The options trading suggests a target price range of $55.0 to $90.0 for VKTX over the next three months. Despite this, professional analysts have set an average price target of $105.6, with varying ratings from Buy to Outperform. VKTX's current stock price is $75.22, with an RSI indicating a potential overbought situation. The company specializes in biopharmaceutical development for metabolic and endocrine disorders.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 5:16 pm

BSGM

LASE

TLRY

VINC

Tilray Brands, Inc. (NASDAQ:TLRY) shares fell by 22% after missing Q3 estimates and revising its fiscal year 2024 outlook. Other stocks showed significant movement, with Laser Photonics Corporation (NASDAQ:LASE) and BioSig Technologies, Inc. (NASDAQ:BSGM) among the top gainers. Vincerx Pharma, Inc. (NASDAQ:VINC) led the losers after presenting preliminary Phase 1 data.

Portfolio Pulse from Avi Kapoor

April 09, 2024 | 5:12 pm

ADBE

Adobe Inc. (NASDAQ:ADBE) shares are trading higher after the launch of Frame.io V4, a content creation and production platform designed to streamline feedback and expedite asset delivery for creative teams. Frame.io V4 extends support for various content types and integrates with other Adobe services, enhancing collaboration for enterprises.

Portfolio Pulse from Nabaparna Bhattacharya

April 09, 2024 | 5:08 pm

GOOGL

NDAQ

SCHW

SPOT

TECK

On CNBC's Halftime Report, analysts shared their final trades, highlighting Nasdaq (NDAQ), Teck Resources (TECK), Charles Schwab (SCHW), Spotify Technology (SPOT), and Alphabet (GOOGL). These picks are seen as significant moves for investors to consider.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 5:02 pm

NCLH

Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) announced plans for eight new ships across three brands, adding nearly 25,000 berths, and the construction of a multi-ship pier at Great Stirrup Cay. The ships are scheduled for delivery between 2026 and 2036, with financing secured for two of the ships. Stifel analyst Steven Wieczynski reiterated a Buy rating with a $25 price target, highlighting the company's aggressive expansion and potential for market entry with minimal fleet cannibalization. Despite a short-term 2.35% drop in NCLH shares to $18.93, the long-term growth prospects are deemed positive.

Portfolio Pulse from Shivani Kumaresan

April 09, 2024 | 5:01 pm

COOP

In the past three months, 5 analysts have updated their ratings on Mr. Cooper Group Inc (NASDAQ:COOP), all shifting to a somewhat bullish stance. The average 12-month price target for COOP has been raised to $83.8, marking a 5.54% increase from the previous target of $79.40. This positive adjustment reflects analysts' growing optimism about the company's performance, underpinned by its solid revenue growth, exceptional net margin, and strong financial health indicators such as ROE and ROA.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 5:00 pm

DLR

Digital Realty Trust's stock (DLR) trades higher following an upgrade by Wells Fargo from Equal-Weight to Overweight and an increase in the price target from $135 to $155.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 4:58 pm

CC

Chemours Co (NYSE:CC) received a double upgrade from BMO Capital Markets, moving from Underperform to Outperform with a price target increase from $19 to $34. This upgrade follows Chemours' Q4 earnings report, which exceeded expectations. Analyst John McNulty highlighted the resolution of accounting issues and potential growth across the company's segments. Despite a lower-than-expected Q1 guidance, McNulty is optimistic about Chemours' performance improvement through 2024, citing effective leadership and strategic planning by CEO Dignam.

Portfolio Pulse from Priya Nigam

April 09, 2024 | 4:56 pm